StockNews.com assumed coverage on shares of Supernus Pharmaceuticals ( NASDAQ:SUPN – Free Report ) in a report released on Thursday morning. The firm issued a hold rating on the specialty pharmaceutical company's stock. Separately, Piper Sandler lowered their target price on Supernus Pharmaceuticals from $46.00 to $43.00 in a research note on Wednesday, July 26th. Supernus Pharmaceuticals Stock Performance NASDAQ SUPN opened at $27.44 on Thursday. The stock has a fifty day moving average of $30.

https://www.dailypolitical.com/2023/10/08/supernus-pharmaceuticals-nasdaqsupn-earns-hold-rating-from-analysts-at-stocknews-com.html

#dailypolitical